Viscosupplementation Market by Product Type, Application and Forecast to 2027 - TMR

Viscosupplementation Reinvented with Biomimetic Polymers to Restore Mobility in OA Patients

An alarming number of individuals suffering from osteoarthritis (OA) has fueled innovation of next-gen viscosupplements. Companies in the viscosupplementation market are increasing efforts to deliver formulations that result in long-lasting pain relief. For instance, Articulate Biosciences— a pre-seed medical device startup, has gained expertise in the development of next-gen, cartilage-protecting viscosupplement that provides significantly longer pain relief to OA patients. The key to success in the market for viscosupplementation is longer pain relief and restoration of mobility in OA patients. Such innovations are bolstering market growth, where the market is estimated to reach a value of ~US$ 4.8 Bn by the end of 2027.

Request Sample Of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10232

Novel biomimetic polymer viscosupplements are increasingly replacing in-development osteoarthritis joint injections. Hence, companies in the viscosupplementation market are increasing R&D in biocompatible polymers, since these polymers are extensively used in FDA-approved stents, contact lenses, and surgical meshes. The market is witnessing a change with the introduction of biocompatible polymers that prevent degradation associated with hyaluronic acid.

Request the Coronavirus Impact Analysis on this Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=10232

Intra-articular Single-injection Viscosupplements Enter List of High-value Therapeutic Solutions

Innovations in intra-articular single-injection viscosupplements are generating revenue opportunities for healthcare companies. This is justified since the revenue of single-injection products is predicted to experience an uptick in the viscosupplementation market. Companies are developing viscosupplements that stay for a prolonged period in the knee joint cavity. For instance, Seikagaku Corporation— a Japan-based pharmaceutical company, announced the launch of HyLink®, a CE marked intra-articular single-injection viscosupplement used for the treatment of knee osteoarthritis through MDM S.p.A., a pharmaceutical company involved in active marketing of high-value therapeutic solutions in Italy. As such, the revenue of knee osteoarthritis application segment is projected for exponential growth in the viscosupplementation market.

Buy _ Research Report Now -

Companies in the market for viscosupplementation are increasing their research efforts in cross-linked hyaluronate hydrogel, which stays longer in the knee joint cavity and offers pain relief for prolonged weeks. Manufacturers in the market for viscosupplementation are setting their collaboration wheels in motion by entering into exclusive distributorship agreements to strategically target OA patients.

Consensus-based Expert Statements to Guide Practitioners on IAHA Implementation

The viscosupplementation market is projected to expand at a CAGR of ~7% during the forecast period. Since companies have established a strong business hold in North America, they are now turning toward Asia Pacific to unearth revenue streams, since this market in Asia Pacific is anticipated for aggressive growth. India being one of the rapidly growing economies of Asia Pacific, is grabbing the attention of healthcare companies and researchers to develop products through deep understanding of patients and clinician needs. However, it has been found that there is a dearth of robust evidence supporting the effectiveness of viscosupplementation or intra-articular hyaluronic acid (IAHA) treatment, which is likely to hamper market growth.

Nonoperative treatment approaches such as viscosupplementation and IAHA delay the need for total knee replacement surgeries in patients who are not ideal candidates for invasive treatment methods. However, the lack of clinical evidence on the safety and effectiveness of IAHA has created barriers for market growth in India. Thus, companies in the viscosupplementation market should increase efforts to collect consensus-based expert statements that can guide practitioners on IAHA use.

Pre Book _ Research Report Now - https://www.transparencymarketresearch.com/checkout.php?rep_id=10232&ltype=S

Combination Therapy of Gel Injection and Knee Bracing Benefit Moderate-grade Knee Arthritis Patients

Apart from knee OA, companies in the viscosupplementation market are seeking value growth by increasing treatment options for hip and hand OA. Manufacturers are increasing their production capabilities to develop innovative synovial fluids that thicken up when pressure is applied and act as shock absorbing materials. The growing availability of synthetic products are triggering the growth of the viscosupplementation market. This is evident since non-animal sourced products are anticipated for exponential growth in the market landscape.

Companies in the market for viscosupplementation are increasing awareness about combination treatments such as gel injections with knee bracing to improve patient outcomes. It has been found that gel injections may be more effective when combined with knee bracing. This combination treatment are benefitting patients with moderate-grade knee arthritis. Likewise, companies are increasing R&D activities to develop combination therapies using stem cell for patients with severe knee arthritis.